Targeting the BCR-ABL1 fusion gene, growth factor receptors (GFRs) and also the RAS-RAF-MEK-ERK pathway, all belong to strategies used in the treatment of myeloid leukemias (Bhullar et al., 2018). The gene discussed is MAP2K7; the disease is myeloid leukemia.